Progressive Supranuclear Palsy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence in the major mature pharmaceutical markets of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. We report the prevalence of PSP for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s PSP forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PSP over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts the following PSP patient population:
- Diagnosed prevalent cases.
Note: Coverage may vary by country.
